Sanofi faces setbacks after itepekimab’s Phase 3 COPD failure, removing a key growth prospect and highlighting reliance on ...

The U.S. FDA has approved an expanded indication for Sanofi (NASDAQ:SNY)’s quadrivalent meningococcal vaccine, MenQuadfi, now ...

Sanofi and Regeneron on Friday reported lackluster late-stage results for their drug candidate in a common lung condition, ...

Regeneron and Sanofi's COPD drug itepekimab cut exacerbations by 27% in one Phase 3 trial, while the second trial did not ...

French drugmaker Sanofi said the U.S. Food and Drug Administration has approved its meningococcal vaccine for use in infants ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

--Down 9.68% month-to-date; on pace for worst month since Oct. 2023, when it fell 15.64% --Up 2.9% year-to-date --Down 16.48% from its all-time closing high of $59.42 on March 6, 2025 --Up 1.22% from ...

Sanofi and Vietnam Vaccine JSC, or VNVC, on Tuesday launched a vaccine manufacturing facility in Vietnam, aimed at producing ...